Bladder cancer surgeons, Drs Cheryl Lee and Khurshid Guru are inspired by a recent Swedish study and discuss aggregate surgical outcomes data comparing their different surgical approaches.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970411). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Guidelines for Perioperative Care After Radical Cystectomy for Bladder Cancer: Enhanced Recovery After Surgery (ERAS®) Society Recommendations https://www.clinicalnutritionjournal.com/article/S0261-5614(13)00254-9/fulltext

Association Between Smoking and Risk of Bladder Cancer Among Men and Women https://jamanetwork.com/journals/jama/fullarticle/1104233/

Robotics in Urology: No More Shadows? https://www.mdpi.com/2673-4397/1/4/28/htm/

Prognostic Impact of Comorbidity in Patients With Bladder Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2262100/

Drs Cheryl Lee and Matthew Galsky superbly synthesize the latest critical elements for sequencing perioperative bladder cancer therapies.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970412). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Multimodal Management of Muscle Invasive Bladder Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190161/

Role of Immunotherapy in Localized Muscle Invasive Urothelial Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461126/

Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795541/

Drs Cheryl Lee and Peter Black share exciting new ways to use liquid biopsy ctDNA testing for bladder cancer diagnostics and patient monitoring.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970413). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Adjuvant Atezolizumab Versus Observation in Muscle-Invasive Urothelial Carcinoma (Imvigor010): A Multicentre, Open-Label, Randomised, Phase 3 Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495594/

ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma https://www.nature.com/articles/s41586-021-03642-9

ClinicalTrials.gov: Treatment of Metastatic Bladder Cancer at the Time of Biochemical reLApse Following Radical Cystectomy (TOMBOLA) https://clinicaltrials.gov/ct2/show/NCT04138628

Drs Cheryl Lee and Sophia Kamran discuss the exciting and evolving role of radiation therapy in treating bladder cancer.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970414). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Trimodality Therapy for Bladder Cancer: Modern Management and Future Directions https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440298/

Adaptive Radiation Therapy for Bladder Cancer: A Review of Adaptive Techniques Used in Clinical Practice https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968556/

Clinical Implementation of Artificial Intelligence-Driven Cone-Beam Computed Tomography-Guided Online Adaptive Radiotherapy in the Pelvic Region https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057957/

Drs Cheryl Lee and Angela Smith discuss bladder cancer research focused on disparities in healthcare affecting women and minorities.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970415). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Bladder Cancer https://www.medscape.com/resource/bladder-cancer

Racial Disparity in Bladder Cancer: Trends in Tumor Presentation at Diagnosis https://www.auajournals.org/doi/10.1016/j.juro.2006.04.074

Sex and Racial Disparities in the Treatment and Outcomes of Muscle-Invasive Bladder Cancer https://linkinghub.elsevier.com/retrieve/pii/S0090-4295(20)30992-4

Drs Cheryl Lee and Sima Porten discuss urinary biomarkers, enhanced cystoscopy, treatments on the horizon, and communication with team members from the cytopathology lab using the PARIS classification.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970416). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Paris System for Reporting Urinary Cytopathology https://paris.soc.wisc.edu/index.htm

Bladder Cancer Biomarkers: Optimal Utilization for Diagnosis and Recurrence https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/93133-bladder-cancer-biomarkers-optimal-utilization-for-diagnosis-and-recurrence-everyday-urology-full-text-article.html

Diagnostic Performance of Oncuria™, a Urinalysis Test for Bladder Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025333/

Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer https://www.frontiersin.org/articles/10.3389/fimmu.2020.615091/full

Drs Cheryl Lee and Stephen Boorjian share detailed insights about a model drug development partnership involving the first-in-class therapy for BCG-unresponsive non–muscle-invasive bladder cancer.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987104). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline (2020) https://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline

ADSTILADRIN (=INSTILADRIN) in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) https://clinicaltrials.gov/ct2/show/NCT02773849

Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988888/

Drs Cheryl Lee and Karim Chamie talk about efforts to develop nogapendekin alfa, aka N-803, and where it may fit into the shifting treatment paradigm for non-muscle invasive bladder cancer.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987105). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

BCG-Unresponsive High-Grade Non-Muscle-Invasive Bladder Cancer: What Does the Practicing Urologist Need to Know? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997797/

Final Clinical Results of Pivotal Trial of IL-15rαfc Superagonist N-803 With BCG in BCG-Unresponsive CIS and Papillary Non-Muscle-Invasive Bladder Cancer (NMIBC) https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4508

PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14) https://www.clincosm.com/trial/pk-sub-quilt-3032-ca-alt-803-01-16-2005-14